Indication
Logibac is indicated for the treatment of individuals with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:
Acute Bacterial Exacerbations of Chronic Bronchitis: Due to Haemophilus influenzae (including β-lactamase producing strains), Moraxella catarrhalis (including β-lactamase producing strains), or Streptococcus pneumoniae (Penicillin – susceptible strains only).
Acute Bacterial Otitis Media: Due to Haemophilus influenzae (including β-lactamase producing strains), Moraxella catarrhalis (including β-lactamase producing strains), or Streptococcus pyogenes.
Pharyngitis and Tonsillitis: Due to Streptococcus pyogenes.
Dosage and Administration
Adults: 400 mg once daily for 10 days. Child: 6months & above 9mg/kg once daily for 10 days.
OR AS DIRECTED BY PHYSICIAN.
Composition
Logibac 400 mg Capsule: Each capsule contains Ceftibuten Dihydrate INN equivalent to Ceftibuten 400 mg.
Logibac 60 ml Powder for Suspension: When reconstituted each 5 ml suspension contains Ceftibuten Dihydrate INN equivalent to Ceftibuten 90 mg.